Onsrud M, Hagen B, Strickert T
Department of Gynecologic Oncology, University Hospital, Trondheim, 7006, Norway.
Gynecol Oncol. 2001 Jul;82(1):167-71. doi: 10.1006/gyno.2001.6233.
The goal of this study was to evaluate the effects of single fractions of 10 Gy pelvic irradiation for palliation and life prolongation in patients with cancer of the uterine cervix or corpus.
A retrospective analysis was performed on 37 cervical cancer and 27 corpus cancer patients treated in the period 1988-1998. All patients had a life expectancy of less than 1 year. Due to stage of disease, age (median 82 years), or comorbidity they were considered unapt for surgery or conventional radiotherapy. Eleven patients with recurrence within irradiated field or early progression received one, 51 patients received two, and 2 patients received three fractions with a 4-week interval.
Vaginal bleeding stopped in 90% and malodorous discharge in 39% of the patients. Among 46 patients with advanced disease treated for palliation, 10 (22%) showed complete tumor responses. Median time to progression was 6 months, and median survival, 9 months. Eighteen patients with early-stage disease and serious comorbidity were treated with life prolongation and symptom prevention as intention, and showed seven complete responses. Median survival was 13 months, and half the deaths were caused by intercurrent disease. Median hospital stay was 5 days and rehabilitation was easy. Fifty-six percent of the patients experienced no acute side effects and 33% had minor gastrointestinal problems. Three patients (6%) had serious late bowel complications, one with a fatal outcome, the symptoms appearing 9-10 months posttreatment.
The 10-Gy single-fraction pelvic radiation regimen is an effective means of symptom palliation and is well tolerated. Tumor responses are obtained. The risk of late bowel complications is a concern for patients with a life expectancy greater than 9 months.
本研究的目的是评估单次10 Gy盆腔照射对子宫颈癌或子宫体癌患者缓解症状及延长生命的效果。
对1988年至1998年期间治疗的37例宫颈癌患者和27例子宫体癌患者进行回顾性分析。所有患者预期寿命均不足1年。由于疾病分期、年龄(中位年龄82岁)或合并症,他们被认为不适合手术或传统放疗。11例照射野内复发或早期进展的患者接受了1次照射,51例患者接受了2次照射,2例患者接受了3次照射,间隔为4周。
90%的患者阴道出血停止,39%的患者恶臭分泌物消失。在46例接受姑息治疗的晚期疾病患者中,10例(22%)显示肿瘤完全缓解。中位进展时间为6个月,中位生存期为9个月。18例早期疾病且合并严重疾病的患者以延长生命和预防症状为目的接受治疗,显示7例完全缓解。中位生存期为13个月,一半的死亡是由并发疾病引起的。中位住院时间为5天,康复容易。56%的患者未出现急性副作用,33%的患者有轻微胃肠道问题。3例患者(6%)出现严重的晚期肠道并发症,1例死亡,症状在治疗后9至10个月出现。
10 Gy单次盆腔放疗方案是缓解症状的有效手段,耐受性良好。可获得肿瘤缓解。对于预期寿命超过9个月的患者,晚期肠道并发症的风险令人担忧。